Addendum

Errata

This article corrects:

  1. Pneumocystis jirovecii: a peculiar fungus posing particular problems for therapy and prophylaxis Volume 55, Issue s1, 1–7, Article first published online: 4 April 2012
  2. Micafungin for candidiasis Volume 55, Issue s1, 8–12, Article first published online: 4 April 2012
  3. Micafungin in haematology Volume 55, Issue s1, 13–23, Article first published online: 4 April 2012
  4. Safety of micafungin in prospective and retrospective clinical trials Volume 55, Issue s1, 58–64, Article first published online: 4 April 2012

The conflicts of interest (COI) statements for the following articles in Vol. 55, Suppl. 1 of Mycoses (first published: April 2012) were not inserted at time of print. The full COI statements have been provided below.

  •  Hof, H. (2012), Pneumocystis jirovecii: a peculiar fungus posing particular problems for therapy and prophylaxis. Mycoses, 55(Suppl. 1): 1-7. doi: 10.1111/j.1439-0507.2011.02159.x
  • The author served as speaker for Pfizer, MSD, Astellas, Gilead.

  •  Pappas, P. G. (2012), Micafungin for candidiasis. Mycoses, 55(Suppl. 1): 8–12. doi: 10.1111/j.1439-0507.2011.02112.x
  • The author has received research grants from Merck, Pfizer, Astellas, T2 Biosystems and Gilead. He is also an ad-hoc advisor for Merck, Astellas, T2 Biosystems and Gilead.

  •  Gamaletsou, M. N., Sipsas, N. V. and Kontoyiannis, D. P. (2012), Micafungin in haematology. Mycoses, 55(Suppl. 1): 13–23. doi: 10.1111/j.1439-0507.2011.02113.x
  • DPK has received research support and honoraria from Schering-Plough, Pfizer, Astellas Pharma, Inc., Enzon Pharmaceuticals, and Merck and Co., Inc. NS and MG have no conflicts of interest to declare.

  •  Ullmann, A. J. and Klaas, W. (2012), Safety of micafungin in prospective and retrospective clinical trials. Mycoses, 55(Suppl. 1): 58–64. doi: 10.1111/j.1439-0507.2011.02116.x
  • AJU has served as a consultant for Astellas Pharma, Basilea, Gilead, MSD, Pfizer and the former Schering-Plough and has participated in speakers’ bureaus for Astellas Pharma, Gilead, MSD, Pfizer and the former Schering-Plough. WK has no conflicts of interest to declare.

Ancillary